[
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26413254",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>A",
        "AA Mutation":"p.T334N",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20512393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23355941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1433A>G",
        "AA Mutation":"p.E478G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>C",
        "AA Mutation":"p.H415P",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22299775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1133T>G",
        "AA Mutation":"p.F378C",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17008892",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1307C>A",
        "AA Mutation":"p.S436Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.937",
        "AA Mutation":"p.K313delinsRGG",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21264552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22299775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>C",
        "AA Mutation":"p.H415P",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1218G>C",
        "AA Mutation":"p.L406F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1000",
        "AA Mutation":"p.T334V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23355941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1370C>G",
        "AA Mutation":"p.S457C",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.883G>A",
        "AA Mutation":"p.D295N",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>A",
        "AA Mutation":"p.F378I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.893A>C",
        "AA Mutation":"p.E298A",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25807654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1006T>G",
        "AA Mutation":"p.F336V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1432G>A",
        "AA Mutation":"p.E478K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.884A>G",
        "AA Mutation":"p.D295G",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1415A>C",
        "AA Mutation":"p.E472A",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25807654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1514T>C",
        "AA Mutation":"p.F505S",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>T",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1006",
        "AA Mutation":"p.F336R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>A",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22870928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.800T>G",
        "AA Mutation":"p.L267R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.884A>G",
        "AA Mutation":"p.D295G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22870928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1219A>T",
        "AA Mutation":"p.M407L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>A",
        "AA Mutation":"p.F378I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04762160",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daratumumab + Dexamethasone + Hyaluronidase-fihj + Pomalidomide + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Rituximab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05551936",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Tazemetostat hydrobromide + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Y646S_OR_EZH2_Y646F_OR_EZH2_Y646H_OR_EZH2_Y646C_OR_EZH2_Y646N_OR_EZH2_A692V_OR_EZH2_A682G",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"This phase II study involved 17 Japanese adult patients with relapsed\/refractory follicular lymphoma (FL), previously treated with chemotherapy without an available standard therapy. The patients   harbored EZH2 activating mutations and were recruited to test the efficacy and safety of the EZH2 inhibitor- Tazemetostat. Tazemetostat was given at 800 mg dose twice a day for 28-days cycle. The objective response rate in this cohort was 76.5%, including six patients who had a complete response and seven who had partial response. The remaining three patients had stable disease status. Finally, the median progression\ufffd\ufffd\ufffdfree survival was not reached at the median follow\ufffd\ufffd\ufffdup of 12.9 months. The authors highlight the efficacy and manageable safety profile of Tazemetostat in refractory\/",
        "rs value":null,
        "pmid":"PubMed:34159682",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EZH2 inhibitor GSK2816126",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02082977",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01897571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HH2853",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04390737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03213665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05627245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SHR2554",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03603951",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03456726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_expression",
        "Disease":"Diffuse Large B-cell Lymphoma Germinal Center B-cell Type",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"In this phase I study, one patient with germinal center B\ufffd\ufffd\ufffdcell\ufffd\ufffd\ufffdlike (GCB) DLBCL and two with non-GCB DLBCL types were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat in Japanese patients with refractory\/relapsed B-cell lymphomas. The patients were treated with a dose of 800 mg twice a day and an objective response was reached only in the patient with the GCB-DLBCL type (complete response), while the other two had progressive disease status. Since EZH2 is known to be expressed in GC and have a role in cellular proliferation and differentiation, the authors speculate that the the cellular origin of DLBCL might be a key in predicting the efficacy of T",
        "rs value":null,
        "pmid":"PubMed:33492746",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Tafasitamab-cxix + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelofibrosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Activating_Mutation",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"In this phase I study, four Japanese patients with follicular lymphoma were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat. Patients were screened for presence of EZH2 mutations and only one patient had an activating mutation in EZH2. The patients were treated with Tazemetostat at a dose of 800 mg twice a day. Three of the four patients had partial response (including the one with the activating mutation), while one had a stable disease status after the treatment cycle. The authors highlight the treatment's acceptable safety profile and promising antitumor activity in relapsed or refractory B-cell lymphomas.",
        "rs value":null,
        "pmid":"PubMed:33492746",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-H\/K-HELP, Survivin-H\/K-HELP,MAGE-A4-H ? K-HELP, MUC1-22 peptide loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04199559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tafasitamab-cxix + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03456726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01897571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02601950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03217253",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03854474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"ovary | carcinoma | clear cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Activating_Mutation",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"Tazemetostat was found to have significantly increased anti-tumor activity in patients with relapsed\/refractory follicular lymphoma with gain-of-function EZH2 mutations (cobas EZH2 Mutation Test; objective response rate of 69%) versus patients with wild-type EZH2 (objective response rate of 35%). Treatment shows good tolerability and durability of response in both groups of patients.",
        "rs value":null,
        "pmid":"PubMed:33035457",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05228158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05467943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Valemetostat tosylate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04842877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Y646H",
        "Disease":"Diffuse Large B-cell Lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial.",
        "rs value":null,
        "pmid":"PubMed:29650362",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozantinib 100\ufffd\ufffd\ufffdmg\/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomized to cabozantinib or placebo. During lead-in phase, 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14\/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 m",
        "rs value":null,
        "pmid":"PubMed:28103611",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01835145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib + Uprosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01979523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DYP688",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05415072",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dacarbazine + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01143402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02359851",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",
        "rs value":null,
        "pmid":"PubMed:22805292",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",
        "rs value":null,
        "pmid":"PubMed:22805292",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14\/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284).",
        "rs value":null,
        "pmid":"PubMed:28103611",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439357",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified_or_GNA11_unspecified_or_BAP1_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01587352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Q209",
        "Disease":"Uveal Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib",
        "Description":"Phase 1 study of MAPK1\/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy.",
        "rs value":null,
        "pmid":"PubMed:23434733",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Q209P",
        "Disease":"Skin Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":"A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.",
        "rs value":null,
        "pmid":"PubMed:24504448",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"JAK1",
        "Genomic Position":"1:65298912-65432187(-) | 1p31.3",
        "CDS Mutation":"c.1507C>T",
        "AA Mutation":"p.Q503*",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27433843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00373373",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02428543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ixazomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02030405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03069352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04867928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Antifungals + DSP-5336",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04988555",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Valproic Acid",
        "Description":"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.",
        "rs value":null,
        "pmid":"PubMed:24797300",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anastrozole + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02730923",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04712942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Revumenib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT04065399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JNJ-75276617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04811560",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KO 539",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04067336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flotetuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05063123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Standard of care + Sulfasalazine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05580861",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin + Gilteritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05199051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daunorubicin",
        "Description":"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.",
        "rs value":null,
        "pmid":"PubMed:22417203",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, PRAME and CMV pp65 transfected TLR7\/8 matured DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01734304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04689815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Cytarabine + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03031249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tretinoin",
        "Description":"ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.",
        "rs value":null,
        "pmid":"PubMed:19059939",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03769532",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Etoposide + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01237808",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Idarubicin + Pegfilgrastim + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00893399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00860639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01296178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01835288",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Pravastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01831232",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04712942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anthracycline + Cytarabine + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05020665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00927498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b + Mini-HCVD",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAF1",
        "Genomic Position":"3:12625100-12705725(-) | 3p25.2",
        "CDS Mutation":null,
        "AA Mutation":"RAF1_Amplification",
        "Disease":"Skin Melanoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Paclitaxel,Sorafenib",
        "Description":"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, \ufffd\ufffd sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.0",
        "rs value":null,
        "pmid":"PubMed:26307133",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAF1",
        "Genomic Position":"3:12625100-12705725(-) | 3p25.2",
        "CDS Mutation":null,
        "AA Mutation":"RAF1_QKI-RAF1",
        "Disease":"Spindle Cell Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Case report of a 27-year old female patient with spindle cell sarcoma. Initial treatment consisted of eight cycles of alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide plus definitive radiation for suspected Ewing's sarcoma. An Archer panel revealed a QKI-RAF1 gene fusion, no EWSR1 and SS18 gene rearrangement were identified and a diagnosis of spindle cell tumor (S100 and CD34 coexpression with recurrent gene fusion) was made. Three months after end of treatment a relapse was diagnosed which progressed under temozolomide-irinotecan. Third-line therapy with trametinib was started which led to a complete metabolic response. The patient died 10months later from septic shock. No tumor progression was noted.",
        "rs value":null,
        "pmid":"PubMed:35050712",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01253070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myeloproliferative neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00217646",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Sorafenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04752527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01664897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00383474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04874194",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03117751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01238211",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Samalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00658814",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + KDS-1001 + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01132586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Etoposide + Mitoxantrone hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01260714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cytarabine + Daunorubicin + Decitabine + Etoposide + Filgrastim + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00416598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic NK cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Entinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00313586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Filgrastim + Fludarabine + Gemtuzumab Ozogamicin + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00801489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + SCH 900776",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01870596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02038153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01361464",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00093470",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01139970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01254578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Azacitidine + Busulfan + Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01168219",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cytarabine",
        "Description":"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:21343560",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00330564",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01436227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00330564",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01015300",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01168440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00673816",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01775930",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ranibizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00089765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludeoxyglucose F 18 + Tanespimycin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00088374",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide + von Hippel-Lindau peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00001703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04068831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | clear cell renal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PT2385",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03108066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | clear cell renal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01372813",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegaptanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00056199",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"autonomic ganglia | paraganglioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belzutifan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04924075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02108002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_Mutation",
        "Disease":"Renal Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3\/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only.",
        "rs value":null,
        "pmid":"PubMed:26951309",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegpleranib + Ranibizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02859441",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vatalanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00052013",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01266070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belzutifan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03401788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00566995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_R200W_(c.598C>T)",
        "Disease":"Chuvash Polycythemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":"Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1\/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.",
        "rs value":null,
        "pmid":"PubMed:27518686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDH1",
        "Genomic Position":"16:68771128-68869451(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CDH1_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib + JMT101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05164848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDH1",
        "Genomic Position":"16:68771128-68869451(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CDH1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03620643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MTL-CEBPA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04105335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01132586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04415008",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01296178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02400281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Pravastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01831232",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00927498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"liver | NS | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MTL-CEBPA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02716012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified_or_DNMT3A_unspecified_or_FLT3_unspecified_or_KMT2A_unspecified_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02473146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified_or_FLT3_unspecified_or_KMT2A_unspecified_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Clofarabine + Cytarabine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00932412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CTNNB1",
        "Genomic Position":"3:41240930-41281936(+) | 3p22.1",
        "CDS Mutation":"c.98C>G",
        "AA Mutation":"p.S33C",
        "Disease":"malignant_melanoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28421416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified_or_FANCB_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCI_unspecified_or_FANCJ_unspecified_or_FANCL_unspecified_or_FANCM_unspecified_or_FANCN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCC",
        "Genomic Position":"9:97861336-98079984(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"FANCC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCF",
        "Genomic Position":"11:22644079-22647387(-) | 11p14.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCF_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCF",
        "Genomic Position":"11:22644079-22647387(-) | 11p14.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCF_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCG",
        "Genomic Position":"9:35073835-35080013(-) | 9p13.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCG_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FOXL2",
        "Genomic Position":"3:138663066-138665982(-) | 3q22.3",
        "CDS Mutation":null,
        "AA Mutation":"FOXL2_C134W",
        "Disease":"ovary | sex cord-stromal tumour | granulosa cell tumour",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ketoconazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01584297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JAK3",
        "Genomic Position":"19:17935595-17958841(-) | 19p13.11",
        "CDS Mutation":null,
        "AA Mutation":"JAK3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pacritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601819",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.170T>G",
        "AA Mutation":"p.F57C",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.103G>A",
        "AA Mutation":"p.V35M",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.373T>A",
        "AA Mutation":"p.C125S",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.374G>C",
        "AA Mutation":"p.C125S",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.376A>G",
        "AA Mutation":"p.N126D",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.179A>C",
        "AA Mutation":"p.Q60P",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q60P",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25705882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.136C>T",
        "AA Mutation":"p.L46F",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.619G>A",
        "AA Mutation":"p.E207K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Cytarabine + Etoposide + Ibrutinib + Melphalan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anastrozole + Miransertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04409639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | juvenile myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Etanercept",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00509600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMARCB1",
        "Genomic Position":"22:24129161-24176703(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"SMARCB1_unspecified",
        "Disease":"soft tissue | epithelioid sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02601950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMARCB1",
        "Genomic Position":"22:24129161-24176703(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"SMARCB1_unspecified",
        "Disease":"soft tissue | synovial sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02601950",
        "source_db":"COSMIC"
    }
]